National Aeronautics and Space Administration June 17, 2011 – Federal Register Recent Federal Regulation Documents

In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration (NASA) announces a meeting of the Astrophysics Subcommittee of the NASA Advisory Council (NAC). This subcommittee reports to the Science Committee of the NAC. The meeting will be held for the purpose of soliciting from the scientific community and other persons, scientific and technical information relevant to program planning.

This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant a partially exclusive license in the United States to practice the inventions described and claimed in USPN 6,047,216, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC- 22724-1, USPN 6,226,553, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-22724-2, USPN 6,223,086, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC- 22724-3, and USPN 6,496,736, Endothelium Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-22724-5 to Meridian Health Systems, P.C., having its principal place of business in Los Angeles, California. The patent rights in these inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.